Skip to main content
. 2019 Oct 1;8(10):1186. doi: 10.3390/cells8101186

Figure 2.

Figure 2

Graphic representation of VAF observed for SNVs in TP53 identified by NGS in blood (reference) and tumor tissue samples, collected at pre-therapy (pre-NACT) at the D-LPS and post-therapy (post-NACT) at the IDS, from a patient with HGSOC. (a) Bar-graph shows VAF decrease in pre- (27.71%) and post-NACT (4.21%) tumor samples, indicating prevalence of the WT “C” allele (blue bar) compared to the Alt “G” allele (yellow bar) at IDS for the TP53 c.215C>G (p.P72R) SNP, present in heterozygosis (57.31%) in the blood reference sample; (b) Bar-graph shows VAF increase in pre- (50.13%) and post-NACT (94.33%) tumor samples highlighting prevalence of the Alt “A” allele (red bar) compared to the WT “G” allele (green bar) in the HGSOC tissue sample collected at IDS of TP53 c.375+1G>A mutation, absent in the blood reference sample (only WT “G” allele, green bar). VAF: variant allele frequency; NACT: neo-adjuvant chemotherapy; HGSOC: high-grade serous ovarian cancer; D-LPS: diagnostic laparoscopy; IDS: interval debulking surgery; Alt: alternative; WT: wild-type.